A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy
ConditionCLL/SLL
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorFei Li
About this trial
Prospective, interventional, and practical clinical studies
Eligibility criteria
Qualifiers
Age between 18 and 70 years, with no gender restrictions;
Patients with CLL/SLL who meet the iwCLL2018 diagnostic criteria;
Indications for treatment
ECOG performance score of 0-2;
Disqualifiers
Has been diagnosed or treated for malignancies other than CLL (including active central nervous system lymphoma) within the past year;
there is clinical evidence of Richter transformation;
Participant cannot receive or plan to receive another treatment during study participation
Other conditions that the investigator considers inappropriate for participation
Trial design
Treatments tested in this trial
- orelabrutinib
- FCR/BR
- BTK inhibitor
Treatment groups
60 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Fei Li
Lead sponsor
The First Affiliated Hospital of Nanchang University
Sponsor institution
Source ClinicalTrials.gov